Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00218413
First received: September 16, 2005
Last updated: January 11, 2017
Last verified: November 2008
  Purpose
Nicotine is highly addictive and many individuals are unable to quit smoking even with treatment. The purpose of this study is to determine the effectiveness of various doses of NicVAX in treating nicotine dependent individuals.

Condition Intervention Phase
Smoking Cessation
Tobacco Use Cessation
Biological: NicVAX
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Anti-nicotine Antibody concentrations [ Time Frame: 19 time points from Day 0 to 365 ]

Secondary Outcome Measures:
  • Smoking cessation [ Time Frame: periods of 2 weeks, 4 weeks, or 12 weeks duration ]
  • Fagerstrom Test for Nicotine Dependence [ Time Frame: 7 time points from Day 0 to 365 ]
  • Safety: vaccine reactogenicity [ Time Frame: 7 days after each dose ]
  • Safety: adverse events [ Time Frame: Day 0-365 ]

Enrollment: 51
Study Start Date: October 2004
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Biological: NicVAX
100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Name: 3'-aminomethylnicotine-rEPA conjugate vaccine
Experimental: 2 Biological: NicVAX
200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
Other Name: 3'-aminomethylnicotine-rEPA conjugate vaccine
Experimental: 3 Biological: NicVAX
200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
Other Name: 3'-aminomethylnicotine-rEPA conjugate vaccine
Experimental: 4 Biological: NicVAX
300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Name: 3'-aminomethylnicotine-rEPA conjugate vaccine
Experimental: 5 Biological: NicVAX
400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
Other Name: 3'-aminomethylnicotine-rEPA conjugate vaccine

Detailed Description:
Tobacco use is the single leading preventable cause of death in the United States. Nicotine is an alkaloid that is derived from the tobacco plant responsible for the psychoactive and addictive effects of smoking. Immunotherapy may be useful in preventing and treating nicotine dependent individuals. NicVAX is a nicotine vaccine, a type of immunotherapy that may be effective in smoking cessation and preventing relapse to nicotine. The purpose of this study is to evaluate the safety and efficacy of various dosing levels and dosing frequencies of NicVAX in treating nicotine dependent individuals.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Current smoker
  • Good general health, including mental health
  • Alveolar carbon monoxide level greater than or equal to 10 ppm

Exclusion Criteria:

  • Prior exposure to NicVAX
  • Known allergy to any of the components of NicVAX
  • Use of any smoking cessation aide
  • Pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00218413

Locations
Netherlands
University of Maastricht
Maastricht, Netherlands, 6229 HA
Sponsors and Collaborators
Nabi Biopharmaceuticals
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Gary Horwith Nabi Biopharmaceuticals
Principal Investigator: Arjen De Vos, MD, PhD Nabi Biopharmaceuticals
  More Information

Responsible Party: Arjen DeVos/ Senior Director, Medical Affairs and Clinical Research, Nabi Biopharmaceuticals
ClinicalTrials.gov Identifier: NCT00218413     History of Changes
Other Study ID Numbers: NIDA-17894-2
Nabi-4505
R01-17894-2
DPMC
Study First Received: September 16, 2005
Last Updated: January 11, 2017

Keywords provided by National Institute on Drug Abuse (NIDA):
Vaccine
Immunogenicity
Randomized Controlled Trial
Addiction

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 24, 2017